Rheumatology Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial
Osteoporosis International, 10/06/09

Eastell R et al. – Once-yearly ZOL increased hip and spine BMD vs placebo, assessed by QCT vs DXA. Changes in trabecular bone resulted in increased indices of compressive strength.

Methods

Randomized, controlled trial of once-yearly ZOL
233 women
lumbar spine, total hip, femoral neck, and trochanter assessed by DXA and QCT
Mean percentage changes from baseline and between-treatment differences (ZOL vs placebo, t-test) evaluated

Results

Mean between-treatment differences for lumbar spine BMD were significant by DXA and QCT
Between-treatment differences were significant for trabecular spine , trabecular trochanter ,total hip , and compressive strength indices at femoral neck , and trochanter

<< Previous
Identifying Patients in Financial Need

Next >>
The effect of weight training on bone mineral density and bone...